Literature DB >> 15494874

Hyperammonemia, bane of the brain.

Robert M Cohn1, Karl S Roth.   

Abstract

Ammonia, normally produced from catabolism of amino acids, is a deadly neurotoxin. As such, the concentration of free ammonia in the blood is very tightly regulated and is exceeded by two orders of magnitude by its physiologic derivative, urea. The normal capacity for urea production far exceeds the rate of free ammonia production by protein catabolism under normal circumstances, such that any increase in free blood ammonia concentration is a reflection of either biochemical or pharmacologic impairment of urea cycle function or fairly extensive hepatic damage. Clinical signs of hyperammonemia occur at concentrations > 60 micromol/L and include anorexia, irritability, lethargy, vomiting, somnolence, disorientation, asterixis, cerebral edema, coma, and death; appearance of these findings is generally proportional to free ammonia concentration, is progressive, and is independent of the primary etiology. Causes of hyperammonemia include genetic defects in the urea cycle ("primary") or organic acidemias ("secondary"), as well as genetic or acquired disorders resulting in significant hepatic dysfunction. Thus, because of the neurotoxic implications of hyperammonemia and the typical absence of other specific laboratory abnormalities, appearance of the clinical signs should trigger an emergent search for elevated blood ammonia concentration.

Entities:  

Mesh:

Year:  2004        PMID: 15494874     DOI: 10.1177/000992280404300801

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  8 in total

1.  Aquaporin 4 as a NH3 Channel.

Authors:  Mette Assentoft; Shreyas Kaptan; Hans-Peter Schneider; Joachim W Deitmer; Bert L de Groot; Nanna MacAulay
Journal:  J Biol Chem       Date:  2016-07-19       Impact factor: 5.157

2.  High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase.

Authors:  Katja M J Heitink-Pollé; Berthil H C M T Prinsen; Tom J de Koning; Peter M van Hasselt; Marc B Bierings
Journal:  JIMD Rep       Date:  2012-07-01

Review 3.  Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy.

Authors:  Halina Cichoż-Lach; Agata Michalak
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 4.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

Review 5.  Neurological implications of urea cycle disorders.

Authors:  A L Gropman; M Summar; J V Leonard
Journal:  J Inherit Metab Dis       Date:  2007-11-23       Impact factor: 4.982

6.  Role of nutrition in the management of hepatic encephalopathy in end-stage liver failure.

Authors:  Chantal Bémeur; Paul Desjardins; Roger F Butterworth
Journal:  J Nutr Metab       Date:  2010-12-22

7.  Potential role of Plasmodium falciparum-derived ammonia in the pathogenesis of cerebral malaria.

Authors:  Sammy Kimoloi; Khalid Rashid
Journal:  Front Neurosci       Date:  2015-07-03       Impact factor: 4.677

8.  Hyperammonemia: What Urea-lly Need to Know: Case Report of Severe Noncirrhotic Hyperammonemic Encephalopathy and Review of the Literature.

Authors:  Ruby Upadhyay; Thomas P Bleck; Katharina M Busl
Journal:  Case Rep Med       Date:  2016-09-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.